FEATURED EDITORIAL
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
- The External Partners Delivering The Components Of RNA Therapies
- AI Fills The Decision-Making Gaps In Process Analytical Technology
- Don't Fear The Machine – A Biologist Explains AI In The BioPharma Industry
- Catalent Says It's Not Our Facility; It Belongs To Novo Nordisk
- CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And Culture
- Using Digital Platforms To Find Your CDMO
- FDA Issues New Guidance On Therapeutic Equivalence
GUEST COLUMNISTS
-
![GettyImages-2234439798-AI-Medicine-Trials-Drug-Development]( "CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And Culture")
CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And CultureDiscover strategies for risk-based governance, AI-enabled quality management, stronger collaboration, and fostering a culture that supports long-term operational excellence.
-
![Asian man typing on laptop-GettyImages-1371907414]( "Using Digital Platforms To Find Your CDMO")
Using Digital Platforms To Find Your CDMOIn recent years, digital platforms have emerged to help pharma/biotech companies discover, evaluate, and connect with CDMOs more efficiently. These resources have different functions and limitations.
-
![FDA-GettyImages-1213293784]( "FDA Issues New Guidance On Therapeutic Equivalence")
FDA Issues New Guidance On Therapeutic EquivalenceThe FDA has issued a new guidance document, Evaluation of Therapeutic Equivalence, clarifying the scientific and regulatory principles. What does this mean for drug developers and manufacturers?
-
![July CDMO]( "July 2026 — CDMO Opportunities And Threats Report")
July 2026 — CDMO Opportunities And Threats ReportEach month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
![paylinker-cdmo-GettyImages-1287846309]( "ADC CDMO Selection For Small Biotech")
ADC CDMO Selection For Small BiotechManufacturing is a critical factor in ADC success. Discover how to align CDMO capabilities with molecule complexity, mitigate risks, and navigate capacity limits.
-
![innovation, technology, future science-GettyImages-2272380557]( "Europe's ATMP Opportunity Still Requires Local Navigation")
Europe's ATMP Opportunity Still Requires Local NavigationEuropean nations offer a welcoming environment for clinical-phase cell and gene therapies. Don't assume the same flexibility carries through to commercialization.
-
![doctor listening while thinking-GettyImages-669563160]( "The Unspoken Truth About Cell Therapy Product Understanding")
The Unspoken Truth About Cell Therapy Product UnderstandingDevelopers often discover important attributes after it's too late to act on them. A well-designed program asks what's needed for commercialization and works backward.
-
![Automation, engineering-GettyImages-2192972387]( "Implementing And Optimizing Your eQMS")
Implementing And Optimizing Your eQMSThis article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.
PHARMA OUTSOURCING WHITE PAPERS
-
![cdmo-solid-dose-GettyImages-1432665138]( "Safely Scaling High Potency API Manufacturing")
Safely Scaling High Potency API ManufacturingScaling HPAPI production demands disciplined containment and exposure control. Integrated operating models help manage risk while enabling compliant, reliable scale‑up.
-
![AugustBio_Hiring_Fixed]( "Strategic Hiring For Scalable Success")
Strategic Hiring For Scalable SuccessDiscover how a people-first talent strategy, purpose-driven culture, and cross-functional collaboration come together to support scalable growth and operational excellence in commercial manufacturing.
-
![GettyImages-1309776439-scientists-lab-analysis-manufacturing]( "Challenges And Solution In The Poly (A) Control For Plasmid And mRNA")
Challenges And Solution In The Poly (A) Control For Plasmid And mRNAPoly(A) tail integrity is critical for mRNA stability and translation. Advanced strategies optimize plasmid design, transcription, and purification to ensure consistent poly(A) control for therapeutic success.
-
![GettyImages-1491009758 lab, cell culture]( "Set Your Cell And Gene Therapy Program Up For Success From Day One")
Set Your Cell And Gene Therapy Program Up For Success From Day OnePartner with a specialized CDMO early in your CGT development to ensure a streamlined path from discovery to successful commercialization, avoiding costly pitfalls and delays.
-
![GettyImages-1269956871 vial bottle]( "Overcoming Challenges To High-Concentration Formulation Development")
Overcoming Challenges To High-Concentration Formulation DevelopmentExplore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.
-
![GettyImages-2174865889-scientists-laboratory-equipment-analysis]( "Process Analytical Technology In The ADC Bioconjugation Process")
Process Analytical Technology In The ADC Bioconjugation ProcessIntegrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
